

**CLEAN COPY OF CLAIMS**

1. A recombinant hG-CSF-L-vFc fusion protein comprising hG-CSF, a peptide linker, and a human IgG Fc variant, wherein the human IgG Fc variant comprises a hinge, CH2, and CH3 domains of human IgG1 with Leu234Val, Leu235Ala, and Pro331Ser mutations as SEQ ID NO 22.
2. The recombinant hG-CSF-L-vFc fusion protein of claim 1, wherein the peptide linker (i) comprises about 20 or fewer amino acids; (ii) is present between hG-CSF and the human IgG Fc variant; and (iii) comprises two or more amino acids selected from the group consisting of glycine, serine, alanine, and threonine.
3. The recombinant hG-CSF-L-vFc fusion protein of claim 1, wherein the hG-CSF-L-vFc fusion protein is characterized by an enhanced *in vitro* biological activity of at least 2 fold relative to that of rhG-CSF on a molar basis.
4. A CHO-derived cell line producing the hG-CSF-L-vFc fusion protein of claim 1 in the cell line's growth medium in excess of 10 µg per million cells in a 24 hour period.
5. The CHO-derived cell line producing the hG-CSF-L-vFc fusion protein of claim 4 in the cell line's growth medium in excess of 30 µg per million cells in a 24 hour period.
6. A method for making a recombinant fusion protein comprising hG-CSF, a flexible peptide linker, and a human IgG Fc variant, which method comprises: (a) generating a CHO-derived cell line by transforming the CHO cell line with a gene encoding the recombinant fusion protein comprising hG-CSF; (b) growing the cell line under conditions sufficient for expressing the recombinant fusion protein in the cell line's growth medium at a rate of in excess of 10 µg per million cells in a 24 hour period; and (c) purifying the expressed protein from step (b), wherein the recombinant fusion protein is characterized by an enhanced *in vitro* biological activity of at least 2 fold relative to that of rhG-CSF on a molar basis; and wherein the human IgG Fc variant comprises a hinge, CH2, and CH3

domains of human IgG1 with Leu234Val, Leu235Ala, and Pro331Ser mutations as SEQ ID NO 22.

7. The method of claim 6, wherein in step (b) growing the cell line under conditions sufficient for expressing the recombinant fusion protein in the cell line's growth medium at a rate of in excess of 30  $\mu$ g per million cells in a 24 hour period.
8. The method of claim 6, wherein the flexible peptide linker (i) comprises about 20 or fewer amino acids; (ii) is present between hG-CSF and the human IgG Fc variant; and (iii) comprises two or more amino acids selected from the group consisting of glycine, serine, alanine, and threonine.
9. The method of claim 8, wherein in step (b) growing the cell line under conditions sufficient for expressing the recombinant fusion protein in the cell line's growth medium is at a rate of in excess of 30  $\mu$ g per million cells in a 24 hour period.
10. A method for making a recombinant fusion protein comprising hG-CSF, a flexible peptide linker, and a human IgG Fc variant, which method comprises: (a) generating a CHO-derived cell line by transforming the CHO cell line with a gene encoding the recombinant fusion protein comprising hG-CSF; (b) growing the cell line under conditions sufficient for expressing the recombinant protein in the cell line's growth medium at rate of in excess of 10  $\mu$ g per million cells in a 24 hour period; and (c) purifying the expressed protein from step (b), wherein the recombinant fusion protein is characterized by an enhanced *in vitro* biological activity of at least 2 fold relative to that of rhG-CSF on a molar basis; wherein the flexible peptide linker (i) comprises about 20 or fewer amino acids; (ii) is present between hG-CSF and the human IgG Fc variant; and (iii) comprises two or more amino acids selected from the group consisting of glycine, serine, alanine, and threonine; and wherein the human IgG Fc variant comprises a hinge, CH2, and CH3 domains selected from the group consisting of human IgG1 with Leu234Val, Leu235Ala, and Pro331Ser mutations as SEQ ID NO 22.


11. The method of claim 10, wherein in step (b) growing the cell line under conditions sufficient for expressing the recombinant fusion protein in the cell line's growth medium at a rate of in excess of 30  $\mu\text{g}$  per million cells in a 24 hour period.

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as express mail in an envelope addressed to Mail Stop Non-Fee Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

January 17, 2007

Date



Hsiang-ning Sun

EB 155779230 US

Express Mail Number